However, its effectiveness in promoting weight loss led to the development of Wegovy, another semaglutide product, specifically approved for chronic weight management
Bergmann NC, Lund A, Gasbjerg LS, Jrgensen NR, Jessen L, Hartmann B, et al
Over 2,000 patients to date have been dosed with HRS9531 across several Phase 1, Phase 2, and Phase 3 clinical trials in China
Some patients, like Jane, have their prescriptions blocked by insurers, scared away by its price tag, through tools like prior authorization (requiring tasks like seeing a specialist in obesity medicine first, or undertaking a weight management program for months before a GLP-1 receptor agonist is on the table)
Por ltimo otro efecto indeseable de este grupo farmacolgico y de todos los mtodos de reduccin de peso es la prdida de masa muscular , especialmente en pacientes con una ingesta proteica insuficiente y que no realizan ejercicios de fuerza, por lo que es recomendable la supervisin y seguimiento de los cambios de composicin corporal en la consulta